Proteolysis

How Proteolysis Works

Proteolytic degradation occurs through several mechanisms:

1. Endopeptidases - Cleave peptide bonds within the protein chain
2. Exopeptidases - Remove amino acids from chain ends
3. Aminopeptidases - Cleave from the N-terminus
4. Carboxypeptidases - Cleave from the C-terminus
5. Dipeptidyl peptidases - Remove dipeptide units (e.g., DPP-4)

Each tissue and body compartment contains different proteolytic enzyme profiles.

Relevance to Peptides

Proteolysis is a central challenge in peptide drug development:

Why Peptides Are Vulnerable

Factor	Impact on Stability
Peptide bonds	Readily cleaved by proteases
L-amino acids	Natural substrates for enzymes
Linear structure	Accessible to exopeptidases
Hydrophilicity	Cannot hide in membranes

Key Proteolytic Enzymes

DPP-4 (Dipeptidyl Peptidase-4)

• Cleaves peptides with alanine or proline at position 2
• Rapidly inactivates GLP-1, GIP, and similar peptides
• Target for diabetes drugs (DPP-4 inhibitors)

Neprilysin

• Degrades natriuretic peptides
• Cleaves at hydrophobic residues

Serum Proteases

• Multiple enzymes in blood plasma
• Major barrier to peptide bioavailability

Strategies to Resist Proteolysis

Peptide chemists use various modifications to improve stability:

Amino Acid Modifications

Strategy	Example	Effect
D-amino acids	Selank, Semax	Resist L-amino acid proteases
N-methylation	Cyclosporine	Block backbone recognition
Unnatural amino acids	Semaglutide (Aib)	Alter enzyme binding
N-terminal acetylation	Various	Block aminopeptidases
C-terminal amidation	Many peptides	Block carboxypeptidases

Structural Modifications

Cyclization

• Reduces conformational flexibility
• Protects both termini
• Examples: Cyclosporine, FOXO4-DRI

Fatty Acid Conjugation

• Semaglutide uses C18 fatty acid
• Promotes albumin binding
• Reduces proteolytic exposure

PEGylation

• Attaches polyethylene glycol chains
• Shields peptide from enzymes
• Extends circulation time

Case Studies in Proteolysis Resistance

GLP-1 and Semaglutide

Native GLP-1:

• Half-life: 2-3 minutes
• Rapidly degraded by DPP-4

Semaglutide modifications:

• Aib at position 8 (resists DPP-4)
• Fatty acid chain (albumin binding)
• Result: Weekly dosing possible

BPC-157 Stability

BPC-157 demonstrates unusual stability:

• Stable in human gastric juice
• Resists various proteases
• Exact mechanism under investigation
• May relate to unique structure

Proteolysis in Drug Design

Consideration	Approach
Oral delivery	Must resist gut proteases
Injection site	Avoid rapid local degradation
Target tissue	May need protection until arrival
Prodrug design	Sometimes use proteolysis for activation

Frequently Asked Questions

Why can’t most peptides be taken orally?

The gastrointestinal tract contains numerous proteolytic enzymes designed to digest dietary proteins. Most peptides are degraded in the stomach and intestines before they can be absorbed. Additionally, the intestinal epithelium has limited permeability to peptides.

How do DPP-4 inhibitor drugs work?

DPP-4 inhibitors (gliptins) block the enzyme that degrades GLP-1 and GIP. By preventing proteolysis of these natural incretins, the drugs extend their activity and improve glucose control. This is different from GLP-1 analogs, which are modified to resist DPP-4 directly.

Are D-amino acid peptides safe?

D-amino acids occur naturally in some bacterial proteins and certain human tissues. D-amino acid substitutions in peptides are generally well-tolerated. However, they can sometimes trigger different immune responses or accumulate differently than L-amino acid peptides.

Does proteolysis serve any beneficial function?

Yes. Proteolysis is essential for protein turnover, signal termination, immune function, and many physiological processes. The challenge in peptide therapeutics is preventing unwanted degradation while maintaining desired proteolytic processes in the body.